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Introduction
Parkinson’s disease was first formally written about in 1817, by 
a prestigious English doctor, James Parkinson. He published a 
short pamphlet about the disease titled, “An Essay on Shaking 
Palsy”. In the beginning of his paper he describes the symptoms 
of the disease as “involuntary tremulous motion, with lessened 
muscular power parts not in action and even when supported; 
with a propensity to bend, with trunk forwards and to pass 
from a walking to running pace; the senses and intellect being 
uninjured”. (Elis, 2013) Parkinson was not the one who discov-
ered the disease as there are sources referencing the disease 
dating back to the ancient Egypt and Mesopotamia. (Raudino, 
2012) As time, technology, and science advanced, scientists and 
medical professionals were able to further understand the caus-
es and symptoms of the disease. Treatment options for those 
suffering from Parkinson’s are as diverse as its symptoms. With 
the advent of modern technology, there are new and innova-
tive treatments that are becoming available. One of these new 
treatments is Deep Brain Stimulation (DBS). As with all new 
treatments, one has to assess its effectiveness, its side effects 
and how it compares with old methods of treatment. This paper 
will address these issues in relation to DBS and its treatment 
for Parkinson’s disease.
Methods
This systematic review was composed after reviewing relevant 
journal articles about the subject matter. Articles used discussed 
causes of the disease, current treatment methods and alterna-
tive surgical interventions. Articles were obtained using search 
engines like Proquest and MedLine and articles from published 
journals.
Background
Prior to exploring treatment options, one must thoroughly 
understand the disease and its causes. Parkinson’s has many 
different causes, some rooted in genetics, others in chemical 
imbalances. The genetic cause for this disease has been shown 
to include five different genes. (Pchelina, et. al. 2014) The first of 
these genetic proteins is ⍺-synuclein, a neuronal protein which 
serves an unknown function. These proteins aggregate in the 
Lewy bodies, causing researchers to conclude that they play 
a major role in the protein composition of the Lewy bodies. 
Although mutations within ⍺-synuclein are relatively rare; even 
patients with sporadic PD seem to exhibit protein aggregates in 
the Lewy bodies, leading researchers to believe that ⍺-synuclein 
plays a major role in both genetic and sporadic forms of PD. 
Several independent family studies done on groups of people 
with PD show that ⍺-synuclein mutations are a rare cause of 
PD. The largest analyses done on ⍺-synuclein and PD indicated 
that allele length variability is associated with an increased risk 
for PD. (Pihlstrøm, Toft, 2011).
Mutations in the gene encoding parkin, a 465 amino acid chain 
protein is one of the causes of autosomal recessive PD. Parkin 
mutations in familial PD suggest that the ubiquitin-protease sys-
tem has an important role in the disease. (Pickrel, Youle, 2015)
Mitochondrial abnormalities are also thought to cause the dis-
ease. These abnormalities lead to a failure of cellular energy 
production and increased free radicals. The newest gene dis-
covered which confirmed these hypotheses is the PINK1 gene. 
(Pickrel, Youle, 2015).
Another gene associated with Parkinson’s is the DJ-1 protein. 
Although its exact function is unknown, it is thought to help 
with proper protein folding. DJ-1 protein may be linked to ab-
normalities in the protein control system. Other studies show 
that DJ-1 mutations may lead to increased levels of oxidative 
stress. (Pchelina, et. al. 2014).
PD is not caused by genetic factors, although genetic factors 
increase one’s risk for developing the disorder. Sporadic PD 
is when there are multiple genetic alterations which increase 
the risk of developing PD, but they do not cause PD. One such 
risk factor is prevalent among Ashkenazi Jews carrying the GBA 
gene mutation. Those who do have a GBA mutation are seven 
times more likely to develop the disease when compared to 
healthy control groups. (Feany, 2004).
The most common cause for PD is from the progressive loss 
of dopaminergic neurons in the substantia nigra pars compac-
ta. Motor symptoms appear when approximately 50%–60% of 
these neurons degenerate, causing a 70%–80% depletion of do-
pamine levels in the dorsal striatum. (Pickrel, Youle, 2015).
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Parkinson’s disease is associated with a wide variety of symp-
toms, both motor and non-motor. The four cardinal motor 
symptoms associated with the disease are; Rest tremor, brady-
kinesia, rigidity and loss of postural reflexes. The rest tremors 
seen in PD are usually found in the distal extremities, but they 
can also be seen in the lips, chin and jaw.  Bradykinesia can be 
described as slow movement and it is a hallmark of basal ganglia 
disorders. Although Parkinson’s patients seem to have impaired 
motor programes, when provided an external stimulus many of 
them exhibit normal movement. This phenomenon is known as 
kinesia paradoxica. Rigidity is often one of the first symptoms of 
the disease, but it is often misdiagnosed as arthritis or bursitis. 
Neck and trunk rigidity leads to postural deformities. Additional 
postural issues include, extreme neck flexion, trunk flexion and/
or scoliosis. (Jankovic, 2008).
Non-motor symptoms associated with the disease include; 
autonomic dysfunction, cognitive abnormalities and sleep 
issues, among others. Autonomic dysfunction features can in-
clude, orthostatic hypotension, sweating dysfunction, sphinc-
ter dysfunction and erectile dysfunction. Neurocognitive 
dysfunction was tested on 537 PD patients using the 
Neuropsychiatric Inventory. Eighty-nine per cent of patients 
exhibited symptoms for at least one of the Neuropsychiatric 
Inventory. The results of the Neuropsychiatric Inventory 
were as follows: Fifty-eight percent of patients showed symp-
toms of depression, 54% showed apathy symptoms, 49% 
exhibited anxiety symptoms and 44% showed signs of hallu-
cinations. (Jankovic, 2008).
Sleep abnormalities often seen in PD were thought to be a side 
effect of the medications patients were given. More recently, 
some physicians are beginning to view it as a part of the disease. 
Researchers began looking at the hypothalamic hypocretin sys-
tem, a system that regulates sleep/wake cycles, to see how this 
system differs in Parkinson’s patients. They have found that pa-
tients with PD had almost 50% fewer hypocretin neurons than 
the healthy control group. (Fronczek, et. al. 2007).
There are no known preventions that will stop PD, however 
there are some substances which have an inverse relationship 
with PD. Caffeine has been found to reduce one’s risk for PD. 
MPTP, one of the toxins associated with PD was injected onto 
the striatum of mice. This led to an 85% decrease in dopamine 
levels in the area. However when the mice were given moderate 
amounts of caffeine, there was only a 60% decrease in dopamine 
levels. This study leads to the conclusion that caffeine may help 
mitigate some of the symptoms of PD, however this relationship 
is not causal. (Holden, 2001).
Nicotine, found in cigarettes, decreases the risk for develop-
ing the disease. It also inhibits the MPTP pathway, ensuring that 
more dopamine receptors remain intact. Additionally, nicotine 
has been shown to reduce the activity of Monoamine Oxidase, 
which causes the oxidation of dopamine. Coffee drinkers have a 
30% decreased risk of developing PD, while smokers have great-
er than a 30% reduction risk. (Martyn, Gale, 2003).
There is no known cure for Parkinson’s Disease, however, 
there are a full array of medications and treatments to slow 
progression of the disease and to relieve some of its symptoms, 
both motor and non-motor. Drug therapy is the mainstay of 
treatment. Surgical intervention, such as deep brain stimula-
tion is recommended in severe cases. Physiotherapy, speech 
therapy and occupational therapy have all been shown to help 
Parkinson’s patients as well, particularly in advanced stages of 
the disease. (Rajput, Rajput, 2006).
The three main drugs being given to Parkinson’s patients are, 
Levodopa, monoamine oxidase B (MAO-B) inhibitors and do-
pamine agonists (DAs). MAO-B inhibitors are given to patients 
with mild motor symptoms, usually in the early stages of the 
disease. When administered in conjunction with Rasagiline, pa-
tients dropped 3-4 points on the Unified Parkinson’s Disease 
Rating Scale. When taken with other drugs, such as SSRIs, 
some patients began exhibiting serotonin syndrome symptoms. 
Dopamine Antagonists act directly on striatal dopamine recep-
tors and have a greater effect on motor symptoms than MAO-B 
inhibitors. DAs are often prescribed as a first order treatment 
in patients who are young at age of onset. Side effects of DAs 
include; nausea, headaches, sleep attacks and Impulsive Control 
Disorder, among others. DAs are usually supplemented with 
levodopa in the later stages of PD. Levodopa, also known as the 
gold standard in PD treatment, is the first order treatment given 
to elderly Parkinson’s patients. Levodopa is most successful at 
eliminating PD motor symptoms, however, it has many side ef-
fects. (Sprenger, Poewe, 2013).
Some side effects of levodopa include nausea and dyskinesia. 
Being on the drug long-term causes up to ⅓ of patients to de-
velop dyskinesias. Between doses patients can experience pain-
ful muscle spasms and the reemergence of other PD symptoms. 
The National Health Service of England recommends keeping 
the dose of levodopa as low as possible to prevent motor com-
plications. The Movement Disorder Society recommends taking 
levodopa with a DA to prevent long-term motor side effects. 
(LeWitt, 2008).
The most common surgical intervention for Parkinson’s patients 
is Deep Brain Stimulation (DBS). Prior to the discovery of this 
treatment, surgical treatment for movement disorders involved 
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ablations. More specifically pallidotomy, thalamotomy, and more 
recently, subthalamatomies. Thalamotomy relieved many of the 
tremors and dopa-induced dyskinesia, however it often left pa-
tients with speech and cognitive deficiencies. Unilateral palli-
dotomy have been shown to significantly improve contralateral 
tremor, rigidity, bradykinesia, and dyskinesias. Side effect of pal-
lidotomy include, weight gain, reduction in verbal fluency, and a 
higher incidence of recurrent depression in patients who have a 
prior history of the disease. Appropriate anatomical and careful 
physiological screening prior to placement of the lesions may 
decrease incidences of cognitive or neuropsychological damage. 
Subthalamatomies have been experimented with as a cheaper 
alternative to DBS. Preliminary findings indicate that there are 
fewer cognitive and speech side effects than in pallidotomy and 
thalamotomy. However postoperative chorea occurred in more 
than half of patients who underwent this procedure. This re-
mains a concern with subthalamotomy. Additional research is 
necessary to ascertain whether this treatment is a viable alter-
native to DBS. (Walter, Vitek, 2004).
Deep brain stimulation is a highly effective surgical therapy 
for PD and other movement disorders (fig. 1). To qualify as a 
candidate for surgery, patients must be first undergo testing 
by a competent neuropsychologist and neurologist. A neurol-
ogist will review the patient’s medical history and ensure that 
reasonable medical intervention has been applied. The patient 
will then meet with a neuropsychologist to discuss goals and 
expectations of the surgery. If a patient has unrealistic expecta-
tions, they are no longer an appropriate candidate for surgery. 
(Benabid, et. al. 2009).  
Once a patient is found to be a viable candidate for surgery, 
they undergo basic preliminary testing. The main test involves 
a patient skipping a dose of levodopa at night. The patient then 
goes to the neurologist so he can assess the patient’s symp-
toms without medication.  Afterwards, the patient then takes 
his dose of levodopa, so the neurologist can see how it affects 
the patient’s symptoms. Symptoms that do not improve with 
medication, usually will not improve with DBS either, hence the 
significance of this test  (Farris, Giroux, 2011).
Once cleared for surgery the patient will undergo the proce-
dure. The procedure involves the implantation of electrodes 
in the subthalamic nucleus, two lead coated wires and a neu-
rostimulator, which is technologically similar to a pacemaker. 
(Farris, Giroux, 2011) Prior to the implantation of the elec-
trodes, patients undergo stereotactic imaging to locate the 
subthalamic nucleus. Surgery for implantation of electrode and 
lead is usually done under local anesthesia, so the surgeon can 
determine the best location for the electrode within the sub-
thalamic nucleus. Using microelectrodes, the surgeon will stimu-
late different areas to figure out where the patient will have the 
greatest symptomatic relief. Once the best tract is found the 
surgeon will replace the microelectrodes with the lead through 
various means. After this is done, the patient is closed up and 
the second part of the procedure takes place at a later date. 
(Benabid, et. al. 2009).
The second part of the procedure involves placing the neuro-
stimulator in the subcutaneous pouch in the subclavicular area. 
This is done under general anesthesia. Once the neurostimula-
tor is inserted and connected to the lead, the programming of 
the stimulator begins. Programming of the neurostimulator will 
usually begin a week after surgery. Voltage is increased gradually, 
while the patient is tested by the neurologist. Once an appropri-
ate setting has been found for the patient, PD medication dos-
ages are lowered to prevent dyskinesias. (Benabid, et. al. 2009).
Deep brain stimulation offers many advantages to ablations, 
although it is not a risk-free procedure. When performing 
ablations, the lesions placed on the brain are permanent and 
irreversible. With DBS, the neurostimulator can be turned off, 
or reprogrammed in case of complications. In cases of adverse 
effects, the neurostimulator can even be explanted. Some of 
the adverse effects of the implantation of the electrodes and 
leads in DBS include hemorrhaging, seizures and/or infection. 
Although these side effects are relatively rare (4%), it is import-
ant to know about them. With regard to the neurostimulator, 
battery depletion is an issue. Batteries have a median life of four 
years, but in patients with high voltage stimulation, they may last 
only one year. (Grill, 2005).
Figure 1  This drawing depicts the components of DBS
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Studies done on the short and long term effects of the pro-
cedure on Parkinson symptoms show significant improvement 
in many of them. Following DBS of the subthalamic nucleus, 
levodopa dosages decreased on average 55.9%. Rigidity and 
bradykinesia symptoms decreased by 63% and 52% respectively 
after twelve months. Parkinsonian tremors decreased by 61% 
following subthalamic nucleus DBS. However, stimulation tar-
geting the dorsal border of the subthalamic nucleus produced 
an 86% improvement in tremor symptoms. Gait and balance 
issues caused by PD are less likely to be helped by DBS. In a 
one year follow up study, patients were found to have the same 
gait and balance scores as their preoperative scores with drug 
treatment. (Fasano, et. Al. 2012).
One must also examine how DBS affects the non-motor symp-
toms of PD. As mentioned above, there are numerous non-mo-
tor symptoms which are part and parcel of the disease and 
DBS effects these symptoms as well in various different ways. 
Cognitively, DBS is safer than all other surgical interventions. 
The vast majority of studies indicate that patients have a decline 
in phonological and semantic verbal fluency tasks. This decline 
is noticeable shortly after surgery and may be the result of mi-
crolesions to the cortical-basal ganglia circuit, which is involved 
with word retrieval. An additional reason for this decline may 
be due to the withdrawal of dopaminergic drugs. Apathy seems 
to worsen following the procedure. This may be caused by the 
inactivation of dopaminergic receptors in the mesocortical and 
mesolimbic pathways after DBS. Many studies show a decrease 
in anxiety following DBS, this may be caused by the relief of 
motor symptoms. DBS seems to have little effect on autonomic 
symptoms of PD. Further research is necessary to better under-
stand this. Sleep symptoms associated with PD, seemed to show 
improvement after DBS. This may be due to decreased bradyki-
nesia and increased bladder capacity. (Fasano, et. Al. 2011).
Conclusion
Deep Brain Stimulation has been proven to be the most effec-
tive surgical intervention for those suffering from Parkinson’s 
Disease. As with most medical issues, invasive surgery is not 
the first choice for treatment, but if necessary DBS is the gold 
standard in invasive treatments for PD. It provides relief to many 
of the motor symptoms associated with the disorder.  Although 
success varies, it has developed into the most viable surgical 
treatment for PD. 
List of Acronyms:
DBS Deep brain stimulation
PD Parkinson’s Disease
MAO-B Monoamine Oxidase B
DA Dopamine Agonists
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